Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel
- 12 October 2014
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 74 (6) , 1113-1124
Abstract
Cabazitaxel is primarily metabolized by CYP3A. This study evaluated the impact of moderate/strong CYP3A inhibitors [aprepitant (Study Part 2); ketoconazole (Study Part 3)] or strong CYP3A inducers [rifampin (Study Part 4)] on the pharmacokinetics of cabazitaxel.Keywords
This publication has 19 references indexed in Scilit:
- Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxelCancer Chemotherapy and Pharmacology, 2013
- Population pharmacokinetics of cabazitaxel in patients with advanced solid tumorsCancer Chemotherapy and Pharmacology, 2013
- Interindividual Variations in Aprepitant Plasma Pharmacokinetics in Cancer Patients Receiving Cisplatin-Based Chemotherapy for the First TimeBiological and Pharmaceutical Bulletin, 2013
- Novel Taxanes: Cabazitaxel Case Study2012
- The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteersBritish Journal of Clinical Pharmacology, 2012
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialThe Lancet, 2010
- Interaction of antitumor platinum complexes with human liver microsomal cytochromes P450Anti-Cancer Drugs, 2009
- Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patientsCancer Chemotherapy and Pharmacology, 2005
- Screening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomesInt. Journal of Clinical Pharmacology and Therapeutics, 2001
- Ketoconazole pharmacokinetics during chronic dosing in adults with haematological malignancyEuropean Journal of Clinical Microbiology & Infectious Diseases, 1986